Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that increases acetylation of histones, leading to a more relaxed chromatin structure and often enhanced transcription. In the context of ZSCAN22, increased histone acetylation could hypothetically interfere with the DNA-binding affinity of ZSCAN22, thereby inhibiting its functional activity as a transcription factor. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that causes hypomethylation of DNA. This can alter the expression of genes and may affect the normal functioning of ZSCAN22 by changing the methylation status of its target gene promoters, potentially reducing its DNA-binding ability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that leads to increased levels of ubiquitinated proteins. If ZSCAN22 is regulated by ubiquitination, MG132 can lead to its accumulation in a misfolded or non-functional state, indirectly inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can downregulate the PI3K/Akt signaling pathway. If ZSCAN22 is downstream of PI3K/Akt and requires it for full activity, inhibition by LY294002 would reduce ZSCAN22 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can block the mTORC1 pathway, potentially leading to reduced protein synthesis. As ZSCAN22 is a transcription factor, its functional activity may be indirectly inhibited by decreased synthesis of proteins that modulate its activity or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that may affect the MAPK signaling pathway. If ZSCAN22's activity is modulated by MAPK signaling, then inhibition by SB203580 could reduce its transcriptional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that interferes with the MEK/ERK pathway. If ZSCAN22 is activated by this pathway, PD98059 can indirectly inhibit its activity by blocking the pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If ZSCAN22 is typically degraded by the proteasome to regulate its levels, bortezomib could lead to the accumulation of non-functional ZSCAN22. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that inhibits calcineurin. If ZSCAN22 is regulated by dephosphorylation through calcineurin, inhibition by cyclosporin A could result in decreased ZSCAN22 activity. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
A CaMKII inhibitor that could disrupt calcium signaling. If ZSCAN22 requires calcium signaling for its activity, inhibition by KN-93 would lead to a functional decrease in ZSCAN22. | ||||||